Key Points
- Director Robert Dunn purchased 200,000 DIAGNOS shares at C$0.30 each, investing C$60,000 and increasing his ownership by 10.43% to 2,117,778 shares.
- DIAGNOS shares opened at C$0.28, with a market capitalization of approximately C$33.11 million and a 12-month trading range of C$0.17 to C$0.41.
- The company provides software-based healthcare services, including a tool that assists professionals in detecting diabetic retinopathy, as well as data-analysis and artificial-intelligence consulting.
DIAGNOS Inc. (CVE:ADK - Get Free Report) Director Robert Dunn purchased 200,000 shares of the business's stock in a transaction that occurred on Wednesday, July 29th. The shares were purchased at an average cost of C$0.30 per share, with a total value of C$60,000.00. Following the completion of the acquisition, the director directly owned 2,117,778 shares in the company, valued at C$635,333.40. The trade was a 10.43% increase in their ownership of the stock.
DIAGNOS Price Performance
CVE:ADK opened at C$0.28 on Friday. The company has a quick ratio of 0.68, a current ratio of 1.49 and a debt-to-equity ratio of 204.05. The firm has a market cap of C$33.11 million, a PE ratio of -6.88 and a beta of -0.12. DIAGNOS Inc. has a 12 month low of C$0.17 and a 12 month high of C$0.41. The company's 50-day moving average price is C$0.24 and its two-hundred day moving average price is C$0.26.
DIAGNOS Company Profile
(
Get Free Report)
DIAGNOS Inc provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
